Triangledisitamab vedotin (NCT04879329)
disitamab vedotin trial for Urothelial Carcinoma (NCT04879329). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable locally advanced or metastatic urothelial cancer. US cohorts require HER2 staining of one-plus, two-plus, or three-plus. Cohorts cover untreated disease or one to two prior lines, with platinum or enfortumab requirements varying by group.
The idea: disitamab vedotin delivers a cell-division-disrupting payload to HER2-bearing cells. Infusions repeat every two weeks. Some first-line groups add pembrolizumab every six weeks. Researchers assess tumor response and safety; only some groups are randomized.
This phase 2 study plans 372 patients. Seagen sponsors; 138 US locations are listed as recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.